©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2020; 26(23): 3170-3181
Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3170
Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3170
Potential of the ellagic acid-derived gut microbiota metabolite – Urolithin A in gastrointestinal protection
Małgorzata Kujawska, Jadwiga Jodynis-Liebert, Department of Toxicology, Poznan University of Medical Sciences, Poznan 60631, Poland
Author contributions: Kujawska M wrote the manuscript; Jodynis-Liebert J revised the manuscript.
Supported by the National Science Centre , No. 2017/26/D/NZ7/00748 .
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Małgorzata Kujawska, MSc, PhD, Adjunct Professor, Associate Professor, Department of Toxicology, Poznan University of Medical Sciences, Dojazd 30, Poznan 60631, Poland. kujawska@ump.edu.pl
Received: January 31, 2020
Peer-review started: January 31, 2020
First decision: April 9, 2020
Revised: May 19, 2020
Accepted: May 23, 2020
Article in press: May 23, 2020
Published online: June 21, 2020
Processing time: 142 Days and 0.4 Hours
Peer-review started: January 31, 2020
First decision: April 9, 2020
Revised: May 19, 2020
Accepted: May 23, 2020
Article in press: May 23, 2020
Published online: June 21, 2020
Processing time: 142 Days and 0.4 Hours
Core Tip
Core tip: Urolithin A (UA) - an ellagitannin metabolite generated by the intestinal bacteria at physiologically relevant micromolar concentrations, offers gastrointestinal (GI) protection. The health benefit is principally related to anticancer and anti-inflammatory effects. UA can regulate multiple tumor and inflammatory signaling pathways and enzyme activities, including those involved in carcinogen biotransformation and antioxidant defense. The presented herein data support the potential of both pure compound and in vivo generated UA in treatment interventions against GI ailments.